跳至主要内容
临床试验/KCT0012407
KCT0012407进行中(未招募)不适用

MR Contrast Media Change for Reduction of Adverse Drug Reaction

Asan Medical Center0 个研究点目标入组 166 人开始时间: 2026年8月24日最近更新:

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
166

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
主要目的
Treatment

入排标准

年龄范围
18(Year) 至 80(Year)(—)
性别
All

入选标准

  • Patients aged 18 to 80 years.
  • Patients with a history of GBCA-related adverse drug reactions, classified as mild or moderate according to Korean clinical practice guidelines
  • Patients who are able to provide relevant information, including the type of GBCA associated with the previous reaction and the type and severity of the previous GBCA-related ADR.
  • Patients with a medical indication for contrast-enhanced MRI.

排除标准

  • Patients who have experienced adverse reactions to two or more different GBCAs.
  • Patients whose previous GBCA-related adverse reaction was caused by gadoxetate disodium.
  • Patients who do not wish to receive premedication.
  • Patients who underwent contrast-enhanced CT or MRI within 24 hours before screening.
  • Patients for whom a specific GBCA has been designated by the Department of Allergy and Immunology.
  • Patients with a history of severe GBCA-related adverse reactions, including anaphylaxis, as defined by Korean clinical practice guidelines.
  • Patients requiring contrast agent administration through a central venous catheter.

研究者

相似试验